AR013094A1 - Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos - Google Patents

Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos

Info

Publication number
AR013094A1
AR013094A1 ARP980102858A ARP980102858A AR013094A1 AR 013094 A1 AR013094 A1 AR 013094A1 AR P980102858 A ARP980102858 A AR P980102858A AR P980102858 A ARP980102858 A AR P980102858A AR 013094 A1 AR013094 A1 AR 013094A1
Authority
AR
Argentina
Prior art keywords
hydrogen
compounds
alkyl
independently selected
represent
Prior art date
Application number
ARP980102858A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR013094A1 publication Critical patent/AR013094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compuestos de urea N-sustituida que comprenden la formula (I) o una sal o solvato farmacéuticamente aceptable del mismo, en donde: A representa N oN-oxido; X representa N, CH o C, de manera que cuando X es N o CH, hay un unico enlace alátomo de carbono 11 segun se representa por la línea solida; ocuando X es C, hay un doble enlace al átomo de carbono 11, segun se representa por las líneas punteada y solida; X1 y X2 son independientemente seleccionadosentre bromo o cloro, y X3 yX4 son independientemente seleccionados, bromo o cloro siempre que por lo menos uno de X3 y X4 sea hidrogeno; Y1 e Y2 sonindependientemente seleccionados entre hidrogeno o alquilo; Z es =O o =S; R5, R6, R7 y R8 cada uno independientementehidrogeno, -C F3, -COR10, alquilo oarilo, y adicionalmente en donde R5 puede combinarse con R6 para representar =O o =S y/o R7 puede combinarse con R8 para representar =O o =S; R10, R19 yR20 representan independientemente hidrogeno, alquilo,alcoxi, arilo,aralq uilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo,heterocicloalquilo y heterocicloalquilalquilo, con la condicion de que R19 y R20 no sean ambos hidrogeno; v es cero, 1, 2 o 3; y W es cero o1;composiciones farmacéuticas que s on inhibidores de la enzima, transferasa de proteína farnesilo y uso de dichos compuestos para preparar medicamentos utilespara inhibir el crecimiento anormal de células.
ARP980102858A 1997-06-17 1998-06-16 Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos AR013094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
AR013094A1 true AR013094A1 (es) 2000-12-13

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102858A AR013094A1 (es) 1997-06-17 1998-06-16 Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos

Country Status (14)

Country Link
EP (1) EP0989979A1 (es)
JP (1) JP2002506444A (es)
KR (1) KR20010013881A (es)
CN (1) CN1267291A (es)
AR (1) AR013094A1 (es)
AU (1) AU8253598A (es)
CA (1) CA2293706C (es)
CO (1) CO4940458A1 (es)
HU (1) HUP0002954A3 (es)
IL (1) IL133389A0 (es)
NZ (1) NZ501571A (es)
PE (1) PE82799A1 (es)
WO (1) WO1998057948A1 (es)
ZA (1) ZA985205B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
HUP0302913A3 (en) * 2000-10-05 2005-05-30 Daley George Q Weston Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
EP1695961A4 (en) * 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC PROCESS FOR SCREENING INHIBITORS OF RAS
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
IL125062A (en) * 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
ES2234036T3 (es) * 1996-09-13 2005-06-16 Schering Corporation Compuestos utiles para inhibir la farnesil-protein-transferasa.
CZ87499A3 (cs) * 1996-09-13 1999-08-11 Schering Corporation Substituované deriváty benzocykloheptapyridinu použitelné při léčbě nádorových onemocnění tím, že inhibují farnesylprotein transferázu

Also Published As

Publication number Publication date
AU8253598A (en) 1999-01-04
IL133389A0 (en) 2001-04-30
JP2002506444A (ja) 2002-02-26
WO1998057948A1 (en) 1998-12-23
CO4940458A1 (es) 2000-07-24
CA2293706A1 (en) 1998-12-23
PE82799A1 (es) 1999-08-26
HUP0002954A2 (hu) 2001-06-28
CN1267291A (zh) 2000-09-20
NZ501571A (en) 2002-02-01
ZA985205B (en) 1998-12-15
KR20010013881A (ko) 2001-02-26
EP0989979A1 (en) 2000-04-05
HUP0002954A3 (en) 2002-11-28
CA2293706C (en) 2008-11-18

Similar Documents

Publication Publication Date Title
AR013094A1 (es) Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
DK0650476T3 (da) Perifert, vasodilaterende middel, der indeholder N-acylerede 4-aminopiperidinderivater som aktive bestanddele
DK365184D0 (da) 1,8-naphthyridinderivater eller estre eller salte deraf, deres fremstilling og anvendelse som farmaceutika
AR003936A1 (es) Compuestos triciclicos y composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento util para inhibir elcrecimiento anormal de celulas.
ES2195034T3 (es) Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
PE20011001A1 (es) Compuestos heterociclicos como inhibidores del intercambio de sodio/protones
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
ES2196772T3 (es) Compuestos amino ciclicos.
CO4910135A1 (es) Derivados cetolidos 6-0 sustituidos de la eritromicina que tienen actividad bacteriana
HUP0400579A2 (hu) Tetralonszármazékok mint tumorellenes gyógyászati hatóanyagok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AR025276A1 (es) El uso de un compuesto que es un derivado de 2-amino-1,3-tiazol, un compuesto que es un derivado de 2-amino-1,3-tiazol, un procedimiento para producirlo y una composicion farmaceutica que lo comprende
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
ES2196806T3 (es) Derivados de fenilurea y de feniltiourea.
TR200100439T2 (tr) 1H-İmidazopiridin türevleri
HUP0400694A2 (hu) A rotamáz enzim aktivitásának kis molekulájú inhibitorai, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények
HUP0000121A2 (hu) Farnezil-protein transzferáz triciklusos inhibitorai, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
DK39286D0 (da) Imidazolderivater, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende disse derivater
AR019674A1 (es) Compuestos antitromboticos y composiciones farmaceuticas que los contienen
ES2094146T3 (es) Derivados de la piridazina, procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE69229637D1 (de) Oxazolidone Derivative als Monoamine-Oxidaseinhibitoren
ES2166098T3 (es) Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure